A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)
Clinical trial NCT03234712 · COMPLETED
Trial details
- NCT number
- NCT03234712
- Sponsor
- AbbVie
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2017-10-10
- Primary completion
- 2021-04-14
- Enrollment
- 62
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.